Guidelines on the use of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in patients with peritoneal surface malignancy arising from colorectal or appendiceal neoplasms

Current Oncology

Volumn 22, Issue 2, 2015, Pages e100-e112

  Dube P ^a,b   Sideris, L ^a,b   Law, C ^c,d   Mack, L ^e   Haase, E ^f   Giacomantonio, C ^g   Govindarajan, A ^c,h   Krzyzanowska, M K ⁱ   Major, P ^j   McConnell, Y ^k   Temple, W ^e   Younan, R ^a,l   McCart, J Andrea ^c,h   Canadian Hipec Collaborative Group, ^m  

^a UNIVERSITÉ DE MONTRÉAL   (Canada)

^b MAISONNEUVE ROSEMONT HOSPITAL   (Canada)

^c UNIVERSITY OF TORONTO   (Canada)

^d SUNNYBROOK RESEARCH INSTITUTE   (Canada)

^e UNIVERSITY OF CALGARY   (Canada)

^f UNIVERSITY OF ALBERTA   (Canada)

^g DALHOUSIE UNIVERSITY   (Canada)

^h MOUNT SINAI HOSPITAL   (Canada)

ⁱ PRINCESS MARGARET HOSPITAL   (Canada)

^j JURAVINSKI CANCER CENTRE   (Canada)

^k UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^l CENTRE HOSPITALIER DE L UNIVERSITÉ DE MONTRÉAL   (Canada)

^m NONE

more..

Author keywords

Appendiceal cancer; Carcinomatosis; Colorectal cancer; Cytoreductive surgery; Hyperthermic intraperitoneal chemotherapy; Peritoneal metastasis; Peritoneal surface malignancy; Pseudomyxoma peritonei

Indexed keywords

APPENDIX TUMOR; ARTICLE; CANCER CHEMOTHERAPY; CANCER STAGING; CARCINOMATOSIS; COLORECTAL CANCER; CYTOREDUCTIVE SURGERY; DISEASE ASSOCIATION; DISEASE COURSE; HUMAN; HYPERTHERMIC INTRAPERITONEAL CHEMOTHERAPY; INFORMATION PROCESSING; PERITONEUM CANCER; PERITONEUM METASTASIS; PERITONEUM TUMOR; PRACTICE GUIDELINE; TREATMENT OUTCOME;

EID: 84928259056     PISSN: None     EISSN: 17187729     Source Type: Journal    
DOI: 10.3747/co.22.2058     Document Type: Article

References (89)

1. Schellinx ME, von Meyerfeldt MF, Sugarbaker PH. Peritoneal carcinomatosis from adenocarcinoma of the colon. Cancer Treat Res 1996;81:247–60.
2. Sugarbaker PH, Schellinx ME, Chang D, Koslowe P, Meyerfeldt M. Peritoneal carcinomatosis from adenocarcinoma of the colon. World J Surg 1996;20:585–91.
3. Jacquet P, Vidal-Jove J, Zhu B, Sugarbaker P. Peritoneal carcinomatosis from gastrointestinal malignancy: natural history and new prospects for management. Acta Chir Belg 1994;94:191–7.
4. Elias D, Raynard B, Farkhondeh F, et al. Peritoneal carcinomatosis of colorectal origin. Gastroenterol Clin Biol 2006;30:1200–4.
5. Macri A, Saladino E, Bartolo V, et al. Peritoneal carcinomatosis of colorectal origin. World J Gastrointest Oncol 2010;2:98–101.
6. Elias D, Goere D. Peritoneal carcinomatosis of colorectal origin: recent advances and future evolution toward a curative treatment. Recent Results Cancer Res 2007;169:115–22.
7. Elias D, Dubé P, Blot F, et al. Peritoneal carcinomatosis treatment with curative intent: the Institut Gustave–Roussy experience. Eur J Surg Oncol 1997;23:317–21.
8. Sugarbaker PH. Surgical treatment of peritoneal carcinomatosis: 1988 Du Pont lecture. Can J Surg 1989;32:164–70.
9. Pocard M, Boige V. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for peritoneal colorectal carcinomatosis: a newly validated standard whose contribution remains to be assessed [French]. Bull Cancer 2005;92:151–4.
10. Chua TC, Moran BJ, Sugarbaker PH, et al. Early- and longterm outcome data of patients with pseudomyxoma peritonei from appendiceal origin treated by a strategy of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. J Clin Oncol 2012;30:2449–56.
11. Verwaal VJ, Bruin S, Boot H, van Slooten G, van Tinteren H. 8-Year follow-up of randomized trial: cytoreduction and hyperthermic intraperitoneal chemotherapy versus systemic chemotherapy in patients with peritoneal carcinomatosis of colorectal cancer. Ann Surg Oncol 2008;15:2426–32.
12. Kusamura S, Baratti D, Zaffaroni N, et al. Pathophysiology and biology of peritoneal carcinomatosis. World J Gastrointest Oncol 2010;2:12–18.
13. Dube P, Lasser P, Elias D. Treatment of peritoneal carcinosis of colorectal origin [French]. J Chir (Paris) 1997;134:233–6.
14. Sayag-Beaujard AC, Francois Y, Glehen O, et al. Treatment of peritoneal carcinomatosis in patients with digestive cancers with combination of intraperitoneal hyperthermia and mitomycin C. Bull Cancer 2004;91:E113–32.
15. Elias D, Delperro JR, Sideris L, et al. Treatment of peritoneal carcinomatosis from colorectal cancer: impact of complete cytoreductive surgery and difficulties in conducting randomized trials. Ann Surg Oncol 2004;11:518–21.
16. Sugarbaker PH. Treatment of peritoneal carcinomatosis from colon or appendiceal cancer with induction intraperitoneal chemotherapy. Cancer Treat Res 1996;82:317–25.
17. Elias D, Detroz B, Debaene B, et al. Treatment of peritoneal carcinomatosis by intraperitoneal chemo-hyperthermia: reliable and unreliable concepts. Hepatogastroenterology 1994;41:207–13.
18. Elias D, Dubé P, Bonvalot S, et al. Treatment of liver metastases with moderate peritoneal carcinomatosis by hepatectomy and cytoreductive surgery followed by immediate post-operative intraperitoneal chemotherapy: feasibility and preliminary results. Hepatogastroenterology 1999;46:360–3.
19. Elias DM, Pocard M. Treatment and prevention of peritoneal carcinomatosis from colorectal cancer. Surg Oncol Clin N Am 2003;12:543–59.
20. Glehen O, Gilly FN, Boutitie F, et al. on behalf of the French Surgical Association. Toward curative treatment of peritoneal carcinomatosis from nonovarian origin by cytoreductive surgery combined with perioperative intraperitoneal chemotherapy: a multi-institutional study of 1,290 patients. Cancer 2010;116:5608–18.
21. Murphy MK, Black NA, Lamping DL, et al. Consensus development methods, and their use in clinical guideline development. Health Technol Assess 1998;2:1–88.
22. Elias D, Gilly FN, Boutitie F, et al. Peritoneal colorectal carcinomatosis treated with surgery and perioperative intraperitoneal chemotherapy: retrospective analysis of 523 patients from a multicentric French study. J Clin Oncol 2010;28:63–8.
23. Glehen O, Cotte E, Brigand C, Arvieux C, Sayag-Beaujard AC, Gilly FN. Therapeutic innovations in the management of peritoneal carcinomatosis from digestive origin: cytoreductive surgery and intraperitoneal chemotherapy [French]. Rev Med Intern 2006;27:382–91.
24. Wright FC, De Vito C, Langer B, Hunter A on behalf of the Expert Panel on Multidisciplinary Cancer Conference Standards. Multidisciplinary cancer conferences: a systematic review and development of practice standards. Eur J Cancer 2007;43:1002–10.
25. Sugarbaker PH. Surgical responsibilities in the management of peritoneal carcinomatosis. J Surg Oncol 2010;101:713–24.
26. Bloemendaal AL, Verwaal VJ, van Ruth S, Boot H, Zoetmulder FA. Conventional surgery and systemic chemotherapy for peritoneal carcinomatosis of colorectal origin: a prospective study. Eur J Surg Oncol 2005;31:1145–51.
27. Sugarbaker PH. Successful management of microscopic residual disease in large bowel cancer. Cancer Chemother Pharmacol 1999;43(suppl):S15–25.
28. Elias D, Blot F, El Otmany A, et al. Curative treatment of peritoneal carcinomatosis arising from colorectal cancer by complete resection and intraperitoneal chemotherapy. Cancer 2001;92:71–6.
29. Verwaal VJ, van Tinteren H, van Ruth S, Zoetmulder FA. Predicting the survival of patients with peritoneal carcinomatosis of colorectal origin treated by aggressive cytoreduction and hyperthermic intraperitoneal chemotherapy. Br J Surg 2004;91:739–46.
30. de Bree E, Koops W, Kröger R, van Ruth S, Verwaal VJ, Zoetmulder FA. Preoperative computed tomography and selection of patients with colorectal peritoneal carcinomatosis for cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. Eur J Surg Oncol 2006;32:65–71.
31. Sugarbaker PH, Jablonski KA. Prognostic features of 51 colorectal and 130 appendiceal cancer patients with peritoneal carcinomatosis treated by cytoreductive surgery and intraperitoneal chemotherapy. Ann Surg 1995;221:124–32.
32. Sugarbaker PH, Chang D, Koslowe P. Prognostic features for peritoneal carcinomatosis in colorectal and appendiceal cancer patients when treated by cytoreductive surgery and intraperitoneal chemotherapy. Cancer Treat Res 1996;81:89–104.
33. Riss S, Mohamed F, Dayal S, et al. Peritoneal metastases from colorectal cancer: patient selection for cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. Eur J Surg Oncol 2013;39:931–7.
34. Elias D, Sideris L, Pocard M, et al. Results of R0 resection for colorectal liver metastases associated with extrahepatic disease. Ann Surg Oncol 2004;11:274–80.
35. Randle RW, Swett KR, Swords DS, et al. Efficacy of cytoreductive surgery with hyperthermic intraperitoneal chemotherapy in the management of malignant ascites. Ann Surg Oncol 2014;21:1474–9.
36. Hribaschek A, Pross M, Kuhn R, et al. Prevention and treatment of peritoneal carcinomatosis in experimental investigations with CPT-11 and oxaliplatin. Anticancer Drugs 2002;13:605–14.
37. Tabrizian P, Jibara G, Shrager B, et al. Outcomes for cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in the elderly. Surg Oncol 2013;22:184–9.
38. Votanopoulos KI, Newman NA, Russell G, et al. Outcomes of cytoreductive surgery (crs) with hyperthermic intraperitoneal chemotherapy (hipec) in patients older than 70 years; survival benefit at considerable morbidity and mortality. Ann Surg Oncol 2013;20:3497–503.
39. McPartland SJ, Goodman MD. The effect of elevated body mass index on outcomes following cytoreductive surgery with hyperthermic intraperitoneal chemotherapy. Ann Surg Oncol 2014;21:1463–7.
40. Votanopoulos KI, Swords DS, Swett KR, et al. Obesity and peritoneal surface disease: outcomes after cytoreductive surgery with hyperthermic intraperitoneal chemotherapy for appendiceal and colon primary tumors. Ann Surg Oncol 2013;20:3899–904.
41. Marcotte E, Sideris L, Drolet P, et al. Hyperthermic intraperitoneal chemotherapy with oxaliplatin for peritonealcarcinomatosis arising from appendix: preliminary results of a survival analysis. Ann Surg Oncol 2008;15:2701–8.
42. Ronnett BM, Zahn CM, Kurman RJ, Kass ME, Sugarbaker PH, Shmookler BM. Disseminated peritoneal adenomucinosis and peritoneal mucinous carcinomatosis. A clinicopathologic analysis of 109 cases with emphasis on distinguishing pathologic features, site of origin, prognosis, and relationship to “pseudomyxoma peritonei.” Am J Surg Pathol 1995;19:1390–408.
43. Misdraji J, Yantiss RK, Graeme-Cook FM, Balis UJ, Young RH. Appendiceal mucinous neoplasms: a clinicopathologic analysis of 107 cases. Am J Surg Pathol 2003;27:1089–103.
44. Sugarbaker PH. Peritoneal surface oncology: review of a personal experience with colorectal and appendiceal malignancy. Tech Coloproctol 2005;9:95–103.
45. Koh JL, Yan TD, Glenn D, Morris DL. Evaluation of preoperative computed tomography in estimating peritoneal cancer index in colorectal peritoneal carcinomatosis. Ann Surg Oncol 2009;16:327–33.
46. Dromain C, Bisdorff A, Elias D, et al. Computed tomographic features of peritoneal carcinomatosis treated by intraperitoneal chemohyperthermia. J Comput Assist Tomogr 2003;27:327–32.
47. Dromain C, Leboulleux S, Auperin A, et al. Staging of peritoneal carcinomatosis: enhanced ct vs. pet/ct. Abdom Imaging 2008;33:87–93.
48. Pomel C, Appleyard TL, Gouy S, Rouzier R, Elias D. The role of laparoscopy to evaluate candidates for complete cytoreduction of peritoneal carcinomatosis and hyperthermic intraperitoneal chemotherapy. Eur J Surg Oncol 2005;31:540–3.
49. Elias D, Benizri E, Pocard M, Ducreux M, Boige V, Lasser P. Treatment of synchronous peritoneal carcinomatosis and liver metastases from colorectal cancer. Eur J Surg Oncol 2006;32:632–6.
50. Van Sweringen HL, Hanseman DJ, Ahmad SA, Edwards MJ, Sussman JJ. Predictors of survival in patients with high-grade peritoneal metastases undergoing cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. Surgery 2012;152:617–24.
51. Esquivel J, Sticca R, Sugarbaker P, et al. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in the management of peritoneal surface malignancies of colonic origin: a consensus statement. Ann Surg Oncol 2007;14:128–33.
52. de Cuba EM, Kwakman R, Knol DL, Bonjer HJ, Meijer GA, Te Velde EA. Cytoreductive surgery and hipec for peritoneal metastases combined with curative treatment of colorectal liver metastases: systematic review of all literature and meta-analysis of observational studies. Cancer Treat Rev 2013;39:321–7.
53. Elias D, Benizri E, Vernerey D, Eldweny H, Dipietrantonio D, Pocard M. Preoperative criteria of incomplete resectability of peritoneal carcinomatosis from non-appendiceal colorectal carcinoma. Gastroenterol Clin Biol 2005;29:1010–13.
54. Cintron JR, Pearl RK. Colorectal cancer and peritoneal carcinomatosis. Semin Surg Oncol 1996;12:267–78.
55. Verwaal VJ, Boot H, Aleman BM, van Tinteren H, Zoetmulder FA. Recurrences after peritoneal carcinomatosis of colorectal origin treated by cytoreduction and hyperthermic intraperitoneal chemotherapy: location, treatment, and outcome. Ann Surg Oncol 2004;11:375–9.
56. Sugarbaker PH, Bijelic L, Chang D, Yoo D. Neoadjuvant folfox chemotherapy in 34 consecutive patients with mucinous peritoneal carcinomatosis of appendiceal origin. J Surg Oncol 2010;102:576–81.
57. Elias D, Lefevre JH, Chevalier J, et al. Complete cytoreductive surgery plus intraperitoneal chemohyperthermia with oxaliplatin for peritoneal carcinomatosis of colorectal origin. J Clin Oncol 2009;27:681–5.
58. Sideris L, Mitchell A, Drolet P, Leblanc G, Leclere YE, Dubé P. Surgical cytoreduction and intraperitoneal chemotherapy for peritoneal carcinomatosis arising from the appendix. Can J Surg 2009;52:135–41.
59. Elias DM. Peritoneal carcinomatosis or liver metastases from colorectal cancer: similar standards for a curative surgery? Ann Surg Oncol 2004;11:122–3.
60. Matsuda K, Hotta T, Takifuji K, et al. Clinical impact of a macroscopically complete resection of colorectal cancer with peritoneal carcinomatosis. Surgery 2012;151:238–44.
61. Maggiori L, Elias D. Curative treatment of colorectal peritoneal carcinomatosis: current status and future trends. Eur J Surg Oncol 2010;36:599–603.
62. Verwaal VJ. Cytoreduction and hipec for peritoneal carcinomatosis from colorectal origin: the Amsterdam experience. Acta Chir Belg 2006;106:283–4.
63. Hildebrandt B, Rau B, Gellermann J, Wust P, Reiss H. Hyperthermic intraperitoneal chemotherapy in patients with peritoneal carcinosis. J Clin Oncol 2004;22:1527–9.
64. Knorr C, Reingruber B, Meyer T, Hohenberger W, Stremmel C. Peritoneal carcinomatosis of colorectal cancer: incidence, prognosis, and treatment modalities. Int J Colorectal Dis 2004;19:181–7.
65. Glehen O, Cotte E, Kusamura S, et al. Hyperthermic intraperitoneal chemotherapy: nomenclature and modalities of perfusion. J Surg Oncol 2008;98:242–6.
66. Elias D, Benizri E, Di Pietrantonio D, Menegon P, Malka D, Raynard B. Comparison of two kinds of intraperitoneal chemotherapy following complete cytoreductive surgery of colorectal peritoneal carcinomatosis. Ann Surg Oncol 2007;14:509–14.
67. Elias D, Bonnay M, Puizillou JM, et al. Heated intra-operative intraperitoneal oxaliplatin after complete resection of peritoneal carcinomatosis: pharmacokinetics and tissue distribution. Ann Oncol 2002;13:267–72.
68. Elias D, El Otmany A, Bonnay M, et al. Human pharmacokinetic study of heated intraperitoneal oxaliplatin in increasingly hypotonic solutions after complete resection of peritoneal carcinomatosis. Oncology 2002;63:346–52.
69. Elias D, Pocard M, Goere D. hipec with oxaliplatin in the treatment of peritoneal carcinomatosis of colorectal origin. Cancer Treat Res 2007;134:303–18.
70. Elias D, Sideris L, Pocard M, et al. Efficacy of intraperitoneal chemohyperthermia with oxaliplatin in colorectal peritoneal carcinomatosis. Preliminary results in 24 patients. Ann Oncol 2004;15:781–5.
71. Elias DM, Sideris L. Pharmacokinetics of heated intraoperative intraperitoneal oxaliplatin after complete resection of peritoneal carcinomatosis. Surg Oncol Clin N Am 2003;12:755–69.
72. Shen P, Hawksworth J, Lovato J, et al. Cytoreductive surgery and intraperitoneal hyperthermic chemotherapywith mitomycin C for peritoneal carcinomatosis from non-appendiceal colorectal carcinoma. Ann Surg Oncol 2004;11:178–86.
73. de Bree E, Witkamp AJ, Zoetmulder FA. Intraperitoneal chemotherapy for colorectal cancer. J Surg Oncol 2002;79:46–61.
74. Sugarbaker PH, Stuart OA, Vidal-Jove J, Pessagno AM, DeBruijn EA. Pharmacokinetics of the peritoneal–plasma barrier after systemic mitomycin C administration. Cancer Treat Res 1996;82:41–52.
75. Glehen O, Kwiatkowski F, Sugarbaker PH, et al. Cytoreductive surgery combined with perioperative intraperitoneal chemotherapy for the management of peritoneal carcinomatosis from colorectal cancer: a multi-institutional study. J Clin Oncol 2004;22:3284–92.
76. Sugarbaker PH. Evolution of cytoreductive surgery and perioperative intraperitoneal chemotherapy for peritoneal carcinomatosis: are there treatment alternatives? Am J Surg 2011;201:157–9.
77. Chua TC, Liauw W, Saxena A, et al. Evolution of locoregional treatment for peritoneal carcinomatosis: single-center experience of 308 procedures of cytoreductive surgery and perioperative intraperitoneal chemotherapy. Am J Surg 2011;201:149–56.
78. Verwaal VJ, Zoetmulder FA. Follow-up of patients treated by cytoreduction and chemotherapy for peritoneal carcinomatosis of colorectal origin. Eur J Surg Oncol 2004;30:280–5.
79. Haslinger M, Francescutti V, Attwood K, et al. A contemporary analysis of morbidity and outcomes in cytoreduction/ hyperthermic intraperitoneal chemoperfusion. Cancer Med 2013;2:334–42.
80. Younan R, Kusamura S, Baratti D, et al. Bowel complications in 203 cases of peritoneal surface malignancies treated with peritonectomy and closed-technique intraperitoneal hyperthermic perfusion. Ann Surg Oncol 2005;12:910–18.
81. Zenasni F, Botella M, Elias D, et al. The long-term impact of hyperthermic intraperitoneal chemotherapy on survivors treated for peritoneal carcinomatosis: a cross-sectional study. Support Care Cancer 2009;17:1255–61.
82. Elias D, Raynard B, Boige V, et al. Impact of the extent and duration of cytoreductive surgery on postoperative hematological toxicity after intraperitoneal chemohyperthermia for peritoneal carcinomatosis. J Surg Oncol 2005;90:220–5.
83. Glehen O, Cotte E, Schreiber V, Sayag-Beaujard AC, Vignal J, Gilly FN. Intraperitoneal chemohyperthermia and attempted cytoreductive surgery in patients with peritoneal carcinomatosis of colorectal origin. Br J Surg 2004;91:747–54.
84. Verwaal VJ, van Ruth S, Witkamp A, Boot H, van Slooten G, Zoetmulder FA. Long-term survival of peritoneal carcinomatosis of colorectal origin. Ann Surg Oncol 2005;12:65–71.
85. Gervais MK, Dubé P, McConnell Y, Drolet P, Mitchell A, Sideris L. Cytoreductive surgery plus hyperthermic intraperitonealchemotherapy with oxaliplatin for peritoneal carcinomatosis arising from colorectal cancer. J Surg Oncol 2013;108:438–43.
86. McQuellon RP, Loggie BW, Fleming RA, Russell GB, Lehman AB, Rambo TD. Quality of life after intraperitoneal hyperthermic chemotherapy (iphc) for peritoneal carcinomatosis. Eur J Surg Oncol 2001;27:65–73.
87. Chua TC. Progress in the combined modality management of peritoneal carcinomatosis. J Surg Oncol 2010;102:728–9.
88. Bonastre J, Chevalier J, Elias D, et al. Cost-effectiveness of intraperitoneal chemohyperthermia in the treatment of peritoneal carcinomatosis from colorectal cancer. Value Health 2008;11:347–53.
89. Canadian Cancer Society’s Advisory Committee on Cancer Statistics. Canadian Cancer Statistics 2013. Toronto, ON: Canadian Cancer Society; 2013. [Available online at: http://www.cancer.ca/~/media/cancer.ca/CW/cancer%20information/cancer%20101/Canadian%20cancer%20statistics/canadiancancer- statistics-2013-EN.pdf; cited February 16, 2014]